Bristol-Myers Squibb Company (BMY)
Bristol Myers's stock pops as earnings top estimates and company raises guidance
The company says it “made important strides in the third quarter.”
Bristol Myers Stock Rises After Earnings Beat, Guidance Hike
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs
Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid as well as newer drugs like heart treatment Camzyos and cancer cell therapy Breyanzi.
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth. The pharmaceutical giant also raised its full-year revenue and adjusted earnings forecast.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Bristol-Myers Squibb, an American multinational pharmaceutical company that discovers, develops, and markets drugs for various therapeutic areas, is now a $108 billion (by market cap) Big Pharma giant. To date, BMY increased its dividend for 15 consecutive years, with a 10-year dividend growth rate of 5%. The company advanced its revenue from $15.9 billion in FY 2014 to $45 billion in FY 2023, a compound annual growth rate of 12.3%.
Bristol Myers Squibb's Q3 Earnings Are Likely To Be Strong
Bristol Myers Squibb remains undervalued with strong long-term potential, despite recent stock price declines and market skepticism about its growth prospects. The company reported strong Q2 FY2024 results, beating expectations with $12.20 billion in sales and $2.07 adjusted EPS, highlighting its growth portfolio's success. BMY's strategic focus on oncology, cardiovascular, and immunology, along with operational excellence and pipeline expansion, positions it well for future growth and recovery.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers (BMY) Upgraded to Buy: Here's What You Should Know
Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMY or VRTX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
